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Abstract
Background: Colorectal cancer (CRC) is the second most common cause of all cancer deaths in Europe and the
Western world with a lifetime risk of approximately 5%. Despite several improvements in the treatment of patients
with unresectable CRC prognosis is poor and there is the need of developing new treatment strategies for patients
with metastatic chemorefractory disease.
The S100 calcium binding protein A4 (S100A4) predicts metastasis formation and reduced CRC patient survival.
S100A4 was previously identified as transcriptional target of the Wnt/β-catenin signaling pathway. The Food and
Drug Administration (FDA)-approved anti-helminthic drug niclosamide is known to intervene in the Wnt/β-catenin
pathway signaling, leading to reduced expression of S100A4 linked to restricted in vivo metastasis formation. Thus,
we aim at translation of our findings on restricting S100A4-driven metastasis into clinical practice for treating
metastasized CRC patients progressing after standard therapy.
Methods/Design: NIKOLO is a phase II, single center, one-arm open-label clinical trial to investigate the safety and
efficacy of niclosamide tablets in patients with metastasized CRC progressing under standard therapy. Eligible patients
will receive 2 g of orally applied niclosamide once a day and will continue with the treatment once daily till disease
progression or toxicity. Toxicities will be graded according to National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI CTCAE) v4.03. The primary objective of this trial is to assess the progression free survival after
4 months, secondary objectives are overall survival, time to progression, disease control rate (remission + partial
remission + stable disease), and safety. Furthermore, pharmacokinetic analysis will be conducted to evaluate
niclosamide plasma concentration.
Discussion: This study is expected to provide evidence of the feasibility, toxicity and efficacy of niclosamide in the
treatment of patients with metastasized CRC and could help to establish a new treatment option.
Trial registration: The study is registered with ClinicalTrials.gov (NCT02519582) and the European Clinical Trials
Database (EudraCT 2014-005151-20).
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Background
Colorectal cancer (CRC) is the second most common
cause of all cancer deaths in Europe and the Western
world with a lifetime risk of approximately 5% [1]. Despite
the implementation of early detection programs about
20–25% of all patients have already synchronous metasta-
ses at the time of diagnosis and approximately 25–50%
will develop metastases in the course of disease mainly in
liver and lung [2, 3]. Liver metastases are the main cause
of death and the only currently available curative therapy
is the surgical R0 resection of metastases. Without any
further treatment the median survival after metastases
detection is poor with about 7.5 month [4].
For patients with unresectable disease several systemic
treatment options are available. In recent years progno-
sis has been improved with median survival rates in clin-
ical trials of up to 30 months [5]. The optimal treatment
strategy is highly depending on the aim of the treatment,
e.g. prolongation of survival, downsizing with secondary
(potentially curative) resection, improving tumor-related
symptoms, stopping tumor progression and/or maintain-
ing quality of life, the side effect profile of the regimen,
tumor -specific factors and comorbidities of the patient.
Combination chemotherapy regimens with 5-fluorouracil/
leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucov-
orin/irinotecan (FOLFIRI) provide higher response rates,
longer progression-free survival (PFS) and better overall sur-
vival (OS) in first-line treatment compared to monotherapy
regimens with 5-fluorouracil/leucovorin alone.
For patients with a good performance status and ad-
equate organ function second-line chemotherapy should
be offered. The chemotherapy regime in this situation is
highly depending on the previous therapies, the therapy-
free interval and pre-existing toxicities.
For patients who received an irinotecan-based regimen
as first-line treatment the second-line treatment should
consist of an oxaliplatin-containing combination (FOL-
FOX or capecitabine/oxaliplatin). For patients who received
an oxaliplatin-based regimen as first-line treatment, the
second-line treatment should be irinotecan-based (FOLFIRI
or irinotecan alone) [6, 7].
The combination of conventional chemotherapy with
molecular targeted therapies such as the anti-vascular
endothelial growth factor (anti-VEGF) agents bevacizu-
mab, ramucirumab and aflibercept or the anti-epidermal
growth factor receptor (anti-EGFR) agents cetuximab
and panitumumab should be considered depending on
the tumor biology. After second-line chemotherapy
many patients are still in a good condition to receive
third-line treatment depending on the organ function
and pre-existing toxicities.
Despite the recent improvements in CRC therapy
there is still the need of developing new treatment strat-
egies for patients with metastatic chemorefractory
disease. One important pathway which is constitutively
active in 90% of CRC is the canonical Wnt/β-catenin
pathway [8].
The S100 calcium binding protein A4 (S100A4) was
identified as a Wnt/β-catenin target gene [9]. S100A4,
originally named metastasin 1 (MTS1), is associated with
many physiological processes (e.g. migration, invasion,
wound healing, neovascularisation). S100A4 is able to
induce metastases in different experimental in vitro and
animal models [10–13]. S100A4 is overexpressed in
many different types of cancer [14, 15]. Its overexpres-
sion correlates with poor patients’ prognosis; high
S100A4 levels are prognostic for metachronous metasta-
ses formation and correlate with reduced patient survival
in several cancer types [16–22]. However, S100A4 itself
is not tumorigenic as shown by Ambartsumian et al.
because transgenic mice with an overexpression of
S100A4 do not develop tumors per se [23].
In our own group we identified niclosamide as a tran-
scriptional inhibitor of S100A4 expression by performing
a high throughput screen for the human S100A4
promoter–driven reporter gene expression. Niclosamide
is used since mid of the 1960s as an anti-helminthic
drug which inhibits glucose uptake, oxidative phosphor-
ylation and anaerobic metabolism [24]. Niclosamide is
approved by the Food and Drug Administration (FDA)
and the European medicines agency (EMA) for treat-
ment of tapeworm infections.
Consequently, we demonstrated the efficacy of niclosa-
mide in cell culture by inhibition of S100A4-induced cell
migration and invasion. We identified niclosamide as
anti-metastatic drug in colon cancer xenografted mice
by restriction of liver metastases linked to shorter
survival. In this experimental setting, niclosamide inter-
fered in the Wnt signaling pathway by disrupting the
complexation of β-catenin/TCF with the S100A4 pro-
moter leading to reduced expression of S100A4 [13].
Other studies reported that niclosamide also interfered
with the Wnt signaling pathways by inhibiting Wnt/Friz-
zled 1 signaling or by inducing the degradation of the
Wnt co-receptor low density lipoprotein receptor-related
protein 6 (LRP6) [25, 26]. Osada et al. demonstrated a
niclosamide-induced decrease in Dvl2 expression, leading
to reduced downstream β-catenin signaling [27]. In
hepatocellular cancer cells, niclosamide reduced cell pro-
liferation, induced apoptosis, decreased TOP activity, and
lowered β-catenin, Dvl2 and cyclin D1 levels [28]. Ono et
al. reported niclosamide-induced reduction of prolifera-
tion of primary human leiomyoma cells by inhibiting
Wnt/β-catenin pathway activation, such as inhibited TOP
activity, down-regulated pathway target genes e.g. Axin2,
and reduced nuclear β-catenin translocation [29].
Londoño-Joshi et al. demonstrated niclosamide-reduced
levels of LRP6 and β-catenin for basal-like breast cancers
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[30]. For ovarian cancer, niclosamide treatment resulted in
increased cytotoxicity, reduction of Wnt/β-catenin signal-
ing by TOP assay, and decreased Wnt pathway proteins
e.g. Axin2 and cyclin D1 [31]. King et al. demonstrated
niclosamide-induced abrogation of Wnt7A/β-catenin sig-
naling, inhibition of β-catenin transcriptional activity, cell
viability, and decrease in cell migration [32]. Satoh et al.
showed that niclosamide inhibited cell proliferation,
induced caspase-dependent apoptosis and G1 cell cycle
arrest, and decreased cell migration, reduced the level of
mediators of epithelial-to-mesenchymal transition, and
decreased β-catenin expression, [33]. Functionally, niclo-
samide is able to block further pathways besides Wnt/β-
catenin signaling, known to be decisive for cancer
initiation, progression and metastases [34, 35]. For instance,
it inhibits the mTORC1 activity by lysosomal dysfunction
in different cancer types [36–38], blocks the STAT3 phos-
phorylation and its translocation to the nucleus in prostate
cancer cells [39], and inhibits the NF-κB and Notch
pathways [40, 41]. Thus, niclosamide has been reported as
an anti-cancer molecule in numerous cancer types like
CRC [13], osteosarcoma [42], breast cancer [30, 37], ovarian
cancer [31, 43], prostate cancer [44], non-small cell lung
cancer (NSCLC) [45, 46], glioblastoma [40], head and neck
cancer [47], multiple myeloma, and leukemia [41, 48].
Niclosamide has only little side effects and seems to
be well tolerated even when applied over a long period
[49]. The oral dose of niclosamide for adults in anti-hel-
minthic treatments is 2 g on day one followed by 1 g daily
for 6 consecutive days. The serum concentration of niclosa-
mide after a single dose of 2 g leads to maximal serum con-
centrations of 0.25–6.0 μg/ml which corresponds to the
concentration used on the above mentioned models
[34, 49].
As there is strong evidence from in vitro and in vivo
experiments that niclosamide might be beneficial as
anti-tumorigenic and anti-metastatic drug we designed
the hereafter described clinical trial to investigate the
safety and efficacy of orally applied niclosamide in
patients with metachronous or sychronous metastases of
a CRC who progressed after therapy and for whom no
other standard therapy is available.
Methods/Design
Study aims
This study evaluates the safety and efficacy of orally applied
niclosamide in patients with metachronous or synchronous
metastases of CRC origin, who progressed under previous
therapy.
Study objectives
Primary objective is PFS after 4 months. PFS after 4 months
will be evaluated according to the Response Evaluation Cri-
teria In Solid Tumors (RECIST) Version 1.1.
Secondary objectives are OS, time to progression, dis-
ease control rate (remission + partial remission + stable
disease), and safety.
Pharmacokinetic analysis will be done to investigate
niclosamide plasma concentration and a potential correl-
ation with efficacy.
Study design
The study is a phase II single center, one-arm open-label
clinical trial for patients with metastatic CRC.
Study schedule
The trial has started on August 2015. The estimated
accrual duration is 30 months. The estimated study
completion date is 2018 (final data collection, date for
primary outcome measure). Survival status will be col-
lected for 2 years after registration.
Trial organization
The trial is organised by the Charité Comprehensive Cancer
Center (CCCC) in collaboration with the Max-Delbrück-
Center for Molecular Medicine (MDC), Berlin, Germany.
Statistics
The study is a one-arm open-label clinical trial with in-
terim analyses for futility of patients with metastatic CRC.
A Simon two-stage design will be used to allow early
termination due to futility. The null hypothesis is that
the probability of being free of progression (having
stable disease, partial or complete response) at 4 months
is p0 = 0.25 (H0: p < =p0 = 0.25) estimated according to
the recent literature [50, 51]. This null hypothesis will be
tested with the Binomial test one-sided against the alter-
native H1 (estimated progression-free probability at
4 months of the experimental therapy) p1 = 0.5. Samples
size for both stages were calculated according to the
optimal design after Simon [52].
In the first stage 17 patients will be recruited. If less
than 5 of the first 17 patients are progression-free at
4 months the trial will be terminated prematurely.
Otherwise 20 additional patients will be enrolled (up to
a total of 37 patients).
The null hypothesis will be rejected if at least 13 pa-
tients out of 37 will be free of progression at 4 months.
This design (optimal design after Simon) yields a type I
error rate of 0.046 and a power of 0.902.
Analyses of PFS and OS survival will performed with
Kaplan-Meier-curves, hazard ration will be reported with
95% confidence intervals. For safety analysis the worst tox-
icities in each cycle will be reported according to the
National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) Version 4.03. A
descriptive analysis of adverse events (AEs) and serious
adverse events (SAEs) will be provided.
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Recruitment process
The trial is expected to take up to 30 months to
complete recruitment. Participants will be recruited
from the Charité Universitätsmedizin Berlin. Following
verbal and written study information in form of the pa-
tient information sheet and extensive discussion with a
clinical trial physician, patients will get at least 24 h time
to consider participation.
Patients who meet all the inclusion criteria and none
of the exclusion criteria listed in Table 1 will be invited
to provide written informed consent.
Study intervention and general considerations for dose
modifications
Patients will start the treatment with the oral intake of
2 g niclosamide on day 1 and will continue with the
medication once daily at the same time after a meal till
disease progression or toxicity. Toxicities will be graded
according to NCI CTCAE v4.03.
In case of an allergic reaction or vomiting ≥ grade II
or diarrhoea or nausea or any other toxicity ≥ grade 3
the study medication will be paused until recovery and
consequently reduced by one dose level (500 mg). If
dose reductions to levels less than 1 g or discontinuation
of the study treatment longer than 3 weeks are neces-
sary, the study treatment will be terminated.
Assessments
Patients will be followed up closely for side effects. This
includes physical examinations as well as blood tests.
Additional intensive analyses of niclosamide levels in the
blood will be conducted in the first patient cohort
(patients 1–5) in the first week to examine the absorp-
tion of niclosamide from the intestine and systemic
circulation. To assess efficacy imaging will be performed
every 2 months to evaluate the disease status.
Translational research
Patients will be asked to consent for optional transla-
tional research including analysis of patients’ tumor
tissue and additional blood analysis as described
hereunder.
Analysis of S100A4 expression in patient primary tumors
and/or metastases or recurrent tumors
If available, tumor tissue of the primary tumor and/or
metastasis or recurrent tumor will be collected for
patients who consent for optional translational research
to do further analyses in specific subgroups (responder/
non-responder). These tissues will be analyzed for
S100A4 expression. These initial analyses characterizing
the molecular starting point of the patient, depend on
the availability of the amount of tissue procured for
research purposes.
Analysis of potential niclosamide-induced effects on circu-
lating S100A4 transcripts in patient plasma
The following initial analyses for characterization of the
molecular starting point of the patient will be performed
by using patients’ plasma for determination of the basal
levels of circulating S100A4 transcripts.
Peripheral blood samples will be collected at baseline
and at end of treatment (due to progression, toxicity or
other reasons) for all patients. For patients who con-
sented for the optional translational research additional
blood samples will be collected during routine blood
taking at week 1, week 4 and thereafter monthly until
progression. Blood samples will be used to discover and
validate the prognostic and predictive value of S100A4
as well as for response to niclosamide and to evaluate
relationship between other clinical outcome parameters.
Plasma generation
Immediately after every blood taking, plasma will be
generated. Blood initially collected in EDTA tubes will
be processed in the lab for generation of plasma aliquots
(400 μl volume) which will be stored frozen at − 80 °C.
Analysis will be performed after completion of collection
of all samples.
Additional analyses of further circulating transcripts
such as beta-catenin might follow in patients who
consented for the optional translational research.
Determination of niclosamide plasma concentration
Plasma samples (400 μl) are supplemented with aceto-
nitrile (800 μl) containing naproxen (0.25 μg/ml). The
mixture is vortexed for 30 s and centrifuged at 15000 g
for 20 min at room temperature. An aliqoute of 800 μl
of supernatant is withdrawn and evaporated to dryness
(N2, 50 °C). The samples were reconstituted in 400 μl
dilution solvent consisting of acetonitrile/methanol/
water (5%/5%/90%, v/v/v) and subjected to HPLC.
HPLC (Shimadzu) will be performed with Trentec
Select columns (RP C8 120 ODS3 5 μm; 125 × 3,0 mm
with guard column; mobile phase A: acetonitrile/water/
phosphoric acid (70/30/0.1, v/v/v); mobile phase B:
acetonitrile/water/phosphoric acid (25/75/0.1, v/v/v);
gradient: 0.01 min B 70%; 8 min B 70%; 8.1 min B 0%;
25 min B 0%; 25.1 min B 70%; flow rate: 0.5 ml/min).
Time of analysis is 50 min, injector volume is 100 μl,
detection l ABS [nm] is performed at 250 nm.
HPLC calibration curves of naproxen and niclosamide
are linear in the range of 0.05 to 1 μg/ml concentration
of each analyte of a dilution series in dilution solvent (=
acetonitrile/methanol/water (5%/5%/90%, v/v/v). The
parameters of a linear regression equation are as follows,
naproxen: R2 = 0.9999, y = 216,017×; niclosamide: R2 =
0.9937, y = 230,993× confirming a good linearity for both
analytes.
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Determination of niclosamide in human plasma sam-
ples is done by HPLC (BioTez GmbH, Berlin).
Discussion
Several research groups and our own studies could show
that niclosamide inhibits crucial pathways associated with
proliferation, migration and invasion like the Wnt/β-ca-
tenin pathway, leading to anti-cancer activity of the drug.
Niclosamide is initially EMA- and FDA-approved for anti-
helminthic treatment and has a good safety profile, which
creates a solid basis for repositioning this drug for
alternate uses. Our preclinical studies supported the
strong potential of niclosamide as anti-cancer drug, which
interferes with tumor progression and metastases forma-
tion via S100A4 inhibition. However, its application in
cancer patients has not been investigated in patients yet.
Therefore, the use of niclosamide represents a novel
approach of particularly metastases intervention via inhib-
ition of a defined molecular target, such as S100A4.
To better explore the therapeutic potential of niclosa-
mide there is the need to conduct a clinical trial to
investigate the safety, efficacy and pharmacokinetics of
orally applied niclosamide in cancer patients, and most
importantly, to investigate if niclosamide treatment will
result in prolongation of the PFS of the patients. The
attractiveness of this study is based on the fact that the
drug activity in patients will be correlated with the
molecular analysis of the target molecule S100A4 in pa-
tient’s blood as the easiest accessible liquid biopsy for
the timely monitoring. Furthermore, potential limiting
factors, such as possible intra-individual difference in
the drug absorption rate, will provide important
additional information to what extend this will lead to
variations of its anti-cancer efficacy.
As there is currently no predictive biomarker for re-
sponse to niclosamide available we included an intense
Table 1 Nikolo trial inclusion and exclusion criteria
Inclusion criteria
Disease related
Patients with metachronous or synchronous metastases of a
colorectal cancer progressing under standard therapy
No proven brain metastases
No curative option available
No standard therapy available
At least one metastasis has to be measurable according to
RECIST V 1.1 in X-ray computed tomography or magnetic
resonance imaging (not older than 2 weeks before inclusion
into the trial)
Demographic
Age > 18 years
Eastern Cooperative Oncology Group performance status
ECOG 0–1
Laboratory
Absolute neutrophil count≥ 1.5 × 109/ L
Platelet count≥ 100 × 109/L
Leukocytes≥ 1.0 × 109/L
Hemoglobin ≥ 9.0 g/dL or 5.59 mmol/l
Bilirubin≤ 2 x Upper Limit of Normal (ULN) if not due to
Gilbert’s syndrome
AST≤ 2.5xULN in patients without liver metastases or ≤
5.0xULN in patients with liver metastases
ALT ≤ 2.5xULN in patients without liver metastases or <
5.0xULN in patients with liver metastases
Adequate renal function (creatinine≤ 1.5xULN)
Ethical/Other
Electrocardiography without clinical significant abnormalities
Written informed consent before inclusion according to the
ICH-GCP and national/local regulations
Patients should use adequate birth control measures, during
the study treatment period and for at least 3 months after the
last study treatment
Women of childbearing potential need to have a negative
pregnancy test 72 h before the application of the first dose
of niclosamide
Patients who are breastfeeding must stop breastfeeding
before the first dose of the study drug and not restart till
8 week after the last drug intake
Exclusion criteria
Concurrent conditions
Pregnant or lactating females
Other malignant disease (except colorectal cancer) within the
last 5 years before inclusion in the trial except adequately
treated basal cell carcinoma of the skin or squamous cell
carcinoma of the skin, in situ carcinoma of the cervix. Patients
with a malignant disease in history have to be free of disease
for 5 years
Clinical significant heart disease like e.g. uncontrolled blood
pressure; heart failure NYHA grade > 2; cardiac infarction within
the last 12 months
Table 1 Nikolo trial inclusion and exclusion criteria (Continued)
Known uncontrolled concomitant disease despite treatment like
e.g. chronic obstructive pulmonary disease
Known alcohol or drug abuse
Serious infection
Any psychological, familial, sociological or geographical condition,
potentially hampering compliance with the study protocol and
follow-up schedule
Ethical/Other
Participation in another interventional study within the last 30 days
Known hypersensitivity against a part of the study drug
Life expectancy < 3 months
Human immunodeficiency virus infection or active hepatitis B/C
Patients that are committed to an institution by official or judicial
order
Persons that are depending on the sponsor, investigator or deputy
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translational research program in our study to gain
deeper insights in the mechanisms of niclosamide
mediated anti-cancer activity. Thus, exploring the thera-
peutic potential of niclosamide in colon cancer patients
in correlation to its target molecule S100A4 will enable
us to evaluate this approach for broader uses in cancer
therapy, where Wnt-signaling interference represents a
rationale.
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